Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Meta Expands AI Training With Employee Activity Tracking Tools 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
WESTMINSTER, Colo., March 20, 2017 -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the company has received regulatory approval in Mexico for its Surefire Infusion Systems and Surefire Guiding Catheters used in radioembolization and chemoembolization procedures.
“We developed our devices to enable physicians to treat patients with liver cancer in a highly targeted fashion by delivering the dose to the tumor while sparing healthy tissue,” said James E. Chomas, CEO and President of Surefire Medical. “We are excited to offer our products to the Mexican market and provide innovative delivery technology for various procedures – whether it is first-line treatment, palliative care or bridge to liver transplant.”
Having secured this regulatory approval from Mexico, the company will now market the Surefire Precision 021, Surefire Infusion System mT/LT, and Surefire Guiding Catheters, which are available in three shapes including Axis, SIM1 and Cobra.
Fewer than 20 percent of the 2.2 million worldwide cases of primary or secondary liver cancers are operable. Many can, however, be treated with chemoembolization or radioembolization, minimally invasive direct-to-target procedures.
About Surefire Medical
Surefire Medical, Inc. develops, manufactures and markets targeted delivery devices for the Interventional Oncology markets. Surefire’s core technology consists of a microcatheter with a unique expandable tip that improves tumor uptake while protecting healthy tissue. It enables physicians to target tumors with superior accuracy, control and protection. Learn more: www.surefiremedical.com.
Media contact: Jenna Clark Surefire Medical (303) 717-2339 [email protected]
